
















SYSTEMATIC REVIEW

Impact of antibiotics on the genomic expression of *Pseudomonas aeruginosa* in the East African community: a systematic review

[version 1; peer review: awaiting peer review]

Comfort Danchal Vandu^{1,2}, Ilemobayo Victor Fasogbon ³,
Angela Mumbua Musyoka ³, Abdulganiy Babatunde Agbaje¹,
Anyanwu Chinyere Njideka ¹, Wusa Makena⁴, Emmanuel O. Ikuomola ⁵,
Reuben Samson Dangana ³, Nancy B. Mitaki ³, Ibe Micheal Usman ⁴,
Augustine Oviosun⁴, Herbert Mbyemeire³, Elizabeth Umoren⁵,
Shango Patience Emmanuel Jakheng¹, Solomon A Mbina ³, Esther Ugo Alum ⁶,
Ibrahim Babangida Abubarkar ³, Swase Dominic Terkimbi ³, Siida Robert ³,
Patrick Maduabuchi Aja ³, Ezra Agwu^{1,7}

¹Department of Microbiology, Faculty of Biomedical Sciences, Kampala International University - Western Campus, Bushenyi, Western Region, Uganda

²Department of Medical Laboratory Science, School of Allied Health Sciences, Kampala International University - Western Campus, Bushenyi, Western Region, Uganda

³Department of Biochemistry, Faculty of Biomedical Sciences, Kampala International University- Western Campus, Kampala, Central Region, Uganda

⁴Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University - Western Campus, Bushenyi, Western Region, Uganda

⁵Department of Physiology, Faculty of Biomedical Sciences, Kampala International University - Western Campus, Bushenyi, Western Region, Uganda

⁶Department of Publications and Extension, Kampala International University, Kampala, Central Region, 20000, Uganda

⁷Department of Microbiology and parasitology, University of Rwanda School of Medicine and Pharmacy, Kigali, Kigali City, Rwanda

V1 First published: 19 Sep 2025, 14:951
<https://doi.org/10.12688/f1000research.167441.1>

Latest published: 19 Sep 2025, 14:951
<https://doi.org/10.12688/f1000research.167441.1>

Open Peer Review

Approval Status AWAITING PEER REVIEW

Any reports and responses or comments on the article can be found at the end of the article.

Abstract

Introduction

Antimicrobial resistance (AMR) is a major global health concern, with the greatest burden observed in lower-middle-income countries. Monitoring AMR through a One Health approach is essential to understand the link between clinical, animal, and environmental sources and to develop targeted interventions.

Objectives

This systematic review aimed to assess the impact of antibiotics on gene expression in *Pseudomonas* spp. within the East African Community (EAC).

Methodology

A thorough literature search across Web of Science, Scopus, and PubMed yielded 284 articles, of which 11 met the inclusion criteria after screening. The selected studies came from five EAC countries. Findings showed a high prevalence of AMR in *Pseudomonas aeruginosa*, with over 90% resistance to most antibiotics, except Amikacin, which remained effective likely due to limited usage.

Results and discussion

Common resistance genes identified included carbapenemases such as *bla**NDM-1* and *bla**VIM*. The disc diffusion method was the most commonly used technique (50%). Multidrug-resistant clones like ST244 and ST357 were frequently reported. Environmental isolates had lower resistance rates (54%) compared to clinical strains (73%), suggesting differing selection pressures. Most studies originated from Kenya and Uganda (each 30%), reflecting differences in research capacity and healthcare infrastructure across the region.

Conclusion

These results underscore the urgent need for expanded AMR surveillance, stronger antimicrobial stewardship, and further research to inform public health responses in East Africa.

Keywords

Antimicrobial resistance, *Pseudomonas aeruginosa*, antibiotics, gene expression & environment.

Corresponding author: Angela Mumbua Musyoka (angela2mumbua@gmail.com)

Author roles: **Vandu CD:** Conceptualization, Data Curation, Formal Analysis, Methodology, Resources, Writing – Original Draft Preparation; **Fasogbon IV:** Conceptualization, Formal Analysis, Methodology, Resources, Software, Writing – Original Draft Preparation; **Musyoka AM:** Conceptualization, Formal Analysis, Methodology, Resources, Software, Writing – Original Draft Preparation; **Agbaje AB:** Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Njideka AC:** Conceptualization, Formal Analysis, Investigation, Methodology, Resources, Writing – Original Draft Preparation; **Makena W:** Data Curation, Formal Analysis, Investigation, Project Administration, Validation, Writing – Original Draft Preparation; **Ikuomola EO:** Conceptualization, Formal Analysis, Software, Validation, Visualization, Writing – Original Draft Preparation; **Dangana RS:** Conceptualization, Formal Analysis, Methodology, Software, Writing – Original Draft Preparation; **Mitaki NB:** Conceptualization, Investigation, Resources, Software, Validation, Writing – Original Draft Preparation; **Usman IM:** Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Original Draft Preparation; **Oviosun A:** Conceptualization, Data Curation, Software, Validation, Writing – Original Draft Preparation; **Mbyemeire H:** Conceptualization, Methodology, Resources, Software, Visualization, Writing – Original Draft Preparation; **Umoren E:** Data Curation, Formal Analysis, Resources, Supervision, Writing – Original Draft Preparation; **Emmanuel Jakheng SP:** Conceptualization, Investigation, Methodology, Resources, Writing – Original Draft Preparation; **Mbina SA:** Conceptualization, Formal Analysis, Methodology, Project Administration, Writing – Original Draft Preparation; **Alum EU:** Conceptualization, Methodology, Resources, Supervision, Writing – Original Draft Preparation; **Abubarkar IB:** Conceptualization, Resources, Software, Supervision, Writing – Original Draft Preparation; **Terkimbi SD:** Data Curation, Formal Analysis, Methodology, Resources, Software, Writing – Original Draft Preparation; **Robert S:** Conceptualization, Methodology, Resources, Software, Visualization, Writing – Original Draft Preparation; **Aja PM:** Conceptualization, Formal Analysis, Methodology, Resources, Supervision, Writing – Review & Editing; **Agwu E:** Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2025 Vandu CD *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Vandu CD, Fasogbon IV, Musyoka AM *et al.* **Impact of antibiotics on the genomic expression of *Pseudomonas aeruginosa* in the East African community: a systematic review [version 1; peer review: awaiting peer review]** F1000Research 2025, 14:951 <https://doi.org/10.12688/f1000research.167441.1>

First published: 19 Sep 2025, 14:951 <https://doi.org/10.12688/f1000research.167441.1>

Key findings of the study

- *Pseudomonas aeruginosa* isolates demonstrated substantial resistance to antibiotics, including cefepime, meropenem, levofloxacin, and ticarcillin-clavulanic acid as reported across various studies conducted in East Africa.
- Amikacin was reported to be more effective in more than 90% of the studies reported across East Africa as a potential treatment choice for multidrug-resistant *Pseudomonas* infections in the region.
- Carbapenem-resistant genes such as *blaNDM-1*, *blaVIM*, and *blaOXA-48* were found in a large number of clinical and environmental isolates.
- High-risk clones, such as ST 244 and ST 357 were reported to demonstrate clonal spread of multidrug-resistant *Pseudomonas aeruginosa* across East African healthcare settings.
- The disc diffusion method was the most popular antimicrobial susceptibility testing method (50%), owing to its low cost and simplicity.
- DNA extraction and PCR were used in 30% of the studies whereas more advanced approaches such as whole genome sequencing were less popular due to resource constraints.
- The majority of studies were undertaken in Kenya (30%) and Uganda (30%), with fewer studies in Tanzania and the Democratic Republic of the Congo (20%), demonstrating regional variations in research capacity and healthcare resources.

Introduction

Pseudomonas aeruginosa is one of the most common Gram-negative bacterium that is well-known for its flexibility and plasticity in a variety of contexts, including natural habitats and therapeutic settings.¹ Due to its potential to produce serious infections and its exceptional resistance to antibiotics, its study has attracted a lot of attention globally in recent years.² It has been reported that *P. aeruginosa* is an opportunistic pathogen that mostly affects persons with impaired immune systems. It is commonly linked to hospital-acquired diseases, such as bloodstream infections, pneumonia, and urinary tract infections.³ The numerous resistance mechanisms and environmental adaptability of this bacteria pose significant hurdles in clinical settings.⁴ Through a variety of strategies, such as overexpressing the efflux pump, changing target locations, and forming biofilms, the bacteria can modify its gene expression to acquire resistance.⁵ Because of its intricate regulatory networks that manage gene expression, *P. aeruginosa* can withstand a variety of drugs and thrive in hostile environments.⁶

Exposure to antibiotics can significantly alter *P. aeruginosa* gene expression profiles.⁷ Genes linked to virulence, resistance, and biofilm formation may express differently in response to sub-inhibitory antibiotic doses⁸; exposure to sub-lethal concentrations of antibiotics can induce the expression of efflux pumps such as *MexAB-OprM* and *MexXY*, which actively expel antibiotics from the bacterial cell, thereby reducing their efficacy.^{9,10} For example, it has been demonstrated that exposure to aminoglycosides, like tobramycin, increases the expression of the *arr* gene, which is involved in the production of biofilms.^{11,12} The intricacy of antibiotic-induced gene expression regulation is demonstrated by the similar differential gene expression responses to colistin and tobramycin, which affect both the transcriptional and translational levels.^{13–15} In addition, it has been demonstrated that antibiotics such as ceftazidime and ciprofloxacin activate genes involved in stress response, which improve bacterial survival in harsh environments.^{16,17} *P. aeruginosa*'s gene expression is also highly influenced by environmental factors.¹⁸ A variety of stresses, including variations in pH, temperature, and the availability of nutrients, can cause adaptive reactions in bacteria that increase their ability to survive and spread disease.¹⁹ For instance, in response to external stimuli, the expression of genes involved in quorum sensing and biofilm formation is frequently elevated, which promotes the onset and persistence of infections.²⁰ Disinfectants and heavy metals are two examples of pollutants that can cause stress reactions and encourage horizontal gene transfer, which can help resistance genes proliferate.²¹ Research has indicated that prevalent disinfectants, quaternary ammonium compounds (QACs), can alter the composition of membranes and enhance the expression of genes related to resistance.^{22,23} According to²⁴ and²⁵ virulence factors can also be expressed in response to environmental factors including oxygen levels and nutrition availability, which can alter *P. aeruginosa*'s pathogenicity.

Antibiotic exposure and environmental factors can work in concert to improve *P. aeruginosa*'s capacity for adaptation.²⁶ For instance, because antibiotic resistance genes frequently co-occur on the same genetic material that is mobile, the

presence of heavy metals in the environment might co-select for these genes.^{27,28} According to,²⁹ the co-selection mechanism makes controlling *P. aeruginosa* infections more difficult by increasing the issue of antibiotic resistance. Furthermore, antibiotic pressure and environmental stimuli both affect biofilm development, a critical component of persistent infections that results in an increasing tolerance to antimicrobial drugs.³⁰

Significant clinical implications result from the interplay of *P. aeruginosa* gene expression and environmental variables in conjunction with antibiotic treatment.^{31,32} Treatment plans may become more difficult to implement as a result of the adaptive reactions that environmental stresses and antibiotics can cause.^{16,33,34} Subinhibitory antibiotic doses, for example, can encourage the production of biofilms, which improves the bacterium’s resistance to antimicrobial drugs and the human immune response.^{35,36} To effectively design therapeutic approaches, a thorough understanding of the molecular mechanisms underlying these adaptive responses is crucial due to their dual impact.³⁷

Materials and methods

Literature search

A comprehensive literature search was systematically conducted across the Web of Science (WoS), Scopus, and PubMed databases on May 23, 2024. The search employed the following terms: “antibiotics OR antibacterial,” “environment OR habitat,” “genomic OR DNA OR gene,” “pseudomonas,” and “east Africa.” Boolean operators (AND/OR/NOT), alternative terms, and various delimiters such as quotation marks, parentheses, wildcards, and asterisks (*) were utilized to create the search strategy outlined in Table 1, as reported by.^{38–40} The search was restricted to peer-reviewed articles published in English. The paper selection process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines^{41,42} and followed the inclusion and exclusion criteria presented in Table 2.

Table 1. Search strategies.

Database	Search strategy
Scopus	(antibiotic* OR antibacteria* OR clinical OR environment* OR surrounding* OR habitat*) AND (genom* OR dna OR "deoxiribonucleic acid" OR gene*) AND (pseudomona*) AND (congo OR drc OR somalia OR burundi OR kenya OR rwanda OR "south sudan" OR uganda OR tanzania OR "East Africa Community")
WoS	(antibiotic* OR antibacteria* OR clinical OR environment* OR surrounding* OR habitat*) AND (genom* OR dna OR "deoxiribonucleic acid" OR gene*) AND (pseudomona*) AND (congo OR drc OR somalia OR burundi OR kenya OR rwanda OR "south sudan" OR uganda OR tanzania OR "East Africa Community")
PubMed	((antibiotic*[title/abstract]) or (antibacteria*[title/abstract]) or clinical [title/abstract]) or (environment*[title/abstract]) or (surrounding*[title/abstract]) or (habitat*[title/abstract])) and ((genom*[title/abstract]) or (dna [title/abstract]) or (deoxiribonucleic acid [title/abstract])) and (pseudomona*[title/abstract]) and ((congo [title/abstract]) or (drc [title/abstract]) or (somalia [title/abstract]) or (burundi [title/abstract]) or (kenya [title/abstract]) or (rwanda [title/abstract]) or (south sudan [title/abstract]) or (uganda [title/abstract]) or (tanzania [title/abstract]) or (East Africa Community [title/abstract])) NOT (review [Publication Type]))

Table 2. Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> Studies involving the expression of any virulence or antibiotic-resistant gene in any <i>Pseudomonas spp.</i> 	<ul style="list-style-type: none"> Studies not focusing on gene expression.
<ul style="list-style-type: none"> Studies involving the impact of antibiotics or environment. 	<ul style="list-style-type: none"> Studies that did not describe the impact of antibiotics or environment on gene expression.
<ul style="list-style-type: none"> Studies conducted in East Africa Community. 	<ul style="list-style-type: none"> Studies that are not on <i>Pseudomonas spp</i> were excluded.
<ul style="list-style-type: none"> Peer-reviewed articles published in English. 	<ul style="list-style-type: none"> Non-English publications.
<ul style="list-style-type: none"> Studies involving the expression of any virulence or antibiotic-resistant gene in any <i>Pseudomonas spp.</i> 	<ul style="list-style-type: none"> Studies conducted elsewhere in East Africa Community.

Results

The Web of Science database search produced 93 articles, Scopus yielded 180, and PubMed identified 11, bringing the total to 284 articles across the three databases. The search results from each database were then exported and imported into Rayyan, a platform specifically designed for systematic review processes, where they were screened based on the inclusion and exclusion criteria.⁴³ On the platform, 70 duplicate articles were removed. The remaining 214 records were initially screened by evaluating their titles and abstracts, which led to the exclusion of 116 articles. Following a more detailed full-text review, an additional 87 articles were excluded for not meeting the inclusion criteria. In the end, 11 articles were included in the study after passing the eligibility criteria and quality assessment as presented in **Figure 1**.

Table 5, indicates that the highest number of studies were done in Kenya (4, 40%), followed by Uganda (3, 30%), while Tanzania and the Democratic Republic of Congo have (2, 20%), there were no eligible studies from Burundi, Rwanda, Somalia and South Sudan. These results indicate that there are only a few studies (not up to 50%) done on the impact of antibiotics or the environment, on the gene expression of *Pseudomonas spp* in the East African communities.

Figure 4 shows the methods used in the isolation and identification of *Pseudomonas spp* from the various samples in the studies, it shows that 70% of the studies used the traditional bacteria culture and biomedical tests to identify the organism, while only 10% used other methods as the Bactec automated system, bacterial culture for lipase activity (and under UV light), and the 16S rRNA sequencing for pathogen identification. The popular disc diffusion method of conducting antimicrobial sensitivity testing is used by most of the studies (50%) to identify the resistant *Pseudomonas* species, (20%) used Vitek and the others (10%) used Phoenix automated AST panel, broth microdilution, and agar diffusion methods each.

The most common antibiotic used to determine the resistance profile of the *Pseudomonas spp* is the Imipenem (90%), Amikacin, Ciprofloxacin, Cefepime, and Ceftazidime were used in (70%) of the studies; Ceftriaxone, Piperacillin-Tazobactam, and Gentamycin were used in (50%) of the Studies; Cefotaxime in (30%), while all the other antibiotics (Erythromycin, Clindamycin, Cefoperazone + Sulbactam, Cefpodoxime, Cefixime, Ampicillin, Amoxicillin-Clavulanic acid, Cefuroxime, Ticarcillin-Clavulanic acid, Levofloxacin, Tetracycline, Tigecycline, Minocycline, Aztreonam, Cloxacillin, Zincsulphate, and Colistin) were each used in (10%) of the studies (**Figure 2**). For the methods of genomic characterization, (30%) of the studies used DNA extraction and PCR, (15%) used Whole Genome Sequencing and the Modified Hodge Test for Carbapenemase activity; and (5%) of the studies used only PCR, Quantitative PCR, and Imipenem-EDTA double disk synergy test for metallo-B lactamase activity (**Figure 5**).

From **Table 4**, the different strains of *Pseudomonas aeruginosa* isolated are, the global high-risk strains (ST 244 and ST 357⁵⁶). From the clinical samples; the high-risk strains (ST 357, ST 654), Local High-risk strains (ST 2025, ST 455 & ST




Figure 1. The PRISMA flow chart.




Figure 2. Percentage of antibiotics reported across various studies.

233), Carbapenem-resistant *P. aeruginosa* (ST 316, ST 357, ST 654 & ST 1203;13) were identified. Also, the novel multidrug-resistant clone with a virulence gene (ST 3674) was identified. While in all studies where other species of *Pseudomonas* (*P. pseudoalcaligenes*) were isolated, no further characterization was done to identify the strains.

Discussion

This systematic review was conducted to identify the impact of antibiotics and the environment on the gene expression pattern of *Pseudomonas spp.* This integrates antimicrobial resistance patterns, genomic characterization, and the influence of environmental factors on bacterial behavior. *Pseudomonas aeruginosa* clinical isolates demonstrated a high level of resistance, with resistance observed in nearly all tested antibiotics except Amikacin in some studies.⁴⁵ Antibiotics that demonstrated resistance as reported across various studies include, Cefepime, Ticarcillin-Clavulanic acid, Piperacillin, Meropenem, Levofloxacin, Tetracycline, Tigecycline Minocycline according to⁴⁴ and.⁴⁵ The resistance reported cuts across multiple antibiotic classes, including cephalosporins (e.g., Ceftriaxone, Cefepime), carbapenems (e.g., Imipenem, Meropenem), and fluoroquinolones (e.g., Levofloxacin), with resistance varying across isolates and geographic locations as shown in Figure 2. The disc diffusion method was the most common method utilized, accounting for 50% of the studies. These could be due to its simplicity, cost-effectiveness, availability, and long-standing usage in clinical microbiology to provide reliable results easy to interpret with minimum requirement. More modern methods, such as the Vitek 2 system, were employed in 20% of research, while the Agar diffusion, Broth microdilution, and Phoenix automated AST panel methods were each used in 10% of the studies indicating resource availability differences as summarized in Figure 3.

These antibiotic resistances reported across various studies in East Africa could be driven down by many factors including the unregulated use of antibiotics in the region. Antibiotics are widely available without a prescription in pharmacies and informal marketplaces throughout East Africa. This unrestricted distribution of antibiotics leads to their misuse and overuse, increasing the emergence of resistant strains. Individuals frequently self-medicate, utilize improper doses, or discontinue therapy prematurely, creating an environment favorable to bacterial resistance. The agricultural-wide use of antibiotics in livestock farming in East Africa particularly as growth promoters can also allow resistant bacteria to transfer from animals to humans through the food chain (E.g. milk and meat).

Furthermore, the lack of efficient antimicrobial stewardship programs increases the resistance, as healthcare practitioners frequently use broad-spectrum antibiotics without proper diagnoses. Limited access to second-line drugs, such as amikacin, forces patients to overuse first-line medications, which contributes to resistance. Inadequate infection control procedures and poor cleanliness in healthcare facilities also contribute to the emergence of resistant *Pseudomonas* bacteria. Socioeconomic factors such as poverty and restricted access to healthcare contribute to inappropriate antibiotic usage, while cross-border movement and globalization bring resistant bacteria from other places.




Figure 3. Methods of antimicrobial sensitivity tests.




Figure 4. Methods used in the isolation and identification of *Pseudomonas spp* reported across various studies.

While other antibiotics demonstrated substantial resistance rates, amikacin remained effective in more than 90% of patients.^{45,49} This finding suggests Amikacin’s potential as a treatment for multidrug-resistant *Pseudomonas* infections in the East African Community. Amikacin’s comparatively low resistance may be attributed to its less frequent use compared to other antibiotics in the region. Amikacin, an aminoglycoside, is primarily used for severe infections and is less commonly prescribed than cephalosporins or carbapenems. This limited use helps to sustain its efficacy by reducing the selective pressure for resistance development. Furthermore, because of their potential nephrotoxicity, aminoglycosides need careful dose and monitoring, restricting their normal use and contributing to long-term efficacy.

Furthermore, these findings reveal *Pseudomonas aeruginosa* resistance genes in East Africa Community particularly carbapenem-resistant genes as presented in Table 3. The most common carbapenem-resistant genes reported across various studies include *blaNDM-1*, *blaVIM*, *blaOXA-48*, and others, indicating the existence of MBL producers and carbapenemase-resistant bacteria in the region. *VIM* and *NDM* genes, for example, were reported to be present in both clinical isolates and carbapenem-resistant bacteria, indicating the increased threat of carbapenem resistance.^{44,46} These genes produce carbapenemase enzymes, which break down carbapenem antibiotics, making them useless. The growing use of carbapenems as a last resort for serious infections, notably in metropolitan and referral hospitals in the East African Community, has put major selective pressure on *Pseudomonas* populations. This selection pressure, combined with the frequent horizontal gene transfer enabled by mobile genetic elements such as plasmids, has resulted in the fast

Table 3. *Pseudomonas* resistance and virulence genes detected.

Organism	Genes/Elements isolated	Reference
<i>Pseudomonas aeruginosa</i>	blaNDM-1, blaVIM-1, blaVIM-6, blaOXA-50, VIM-6, NDM-1, crpP, qnrVCi, IMPs, VIM, OXA-48, KPC, NDM, blaIMP1, blaIMP2, blaSPM, blaNDM1, blaVIM, phzB1, exoS, exoU	44
<i>Pseudomonas aeruginosa</i> (clinical isolates)	VIM-6 (ST1203), NDM-1 (ST357), crpP, qnrVCi	45
<i>Pseudomonas aeruginosa</i> (Carbapenem resistant)	Metallo-B-lactase producers (72%), Carbapemase resistant genes: IMPs, VIM, OXA-48, KPC, NDM (10.13%)	46
<i>Pseudomonas aeruginosa</i> (Carbapenemase resistant genes)	blaIMP1 (36%), blaIMP2 (4%), blaVIM1 (32%), blaSPM (20%), blaNDM1 (4%)	47
<i>Pseudomonas aeruginosa</i> (Carbapenemase genes carriage)	blaVIM, No MBL genes detected, No OXA-type carb genes	48
<i>Pseudomonas aeruginosa</i> (Class 1 Integron)	Class 1 Integron (64%), Class 1 Integron genes: aminoglycoside adenylyltransferase (ant(4')-IIB), dihydrofolate reductase (dfrA), adenylyltransferase (aadAB)	49
<i>Pseudomonas aeruginosa</i> (Novel lineages)	XDR, highest number of virulence genes (98%)	50
<i>Pseudomonas aeruginosa</i> (CRPA)	blaVIM genes successfully transferred to <i>E. coli</i> (25%), All isolates have 3 virulence genes	51
<i>Pseudomonas spp</i>	Highest lipolytic activity, Pre and Post - circumcision, <i>Pseudomonas</i> clusters	54
<i>Pseudomonas pseudoalcaligenes</i> , <i>P. stutzeri</i>	No specific genes mentioned	52
<i>Pseudomonas stanieri</i> , <i>P. aeruginosa</i> , <i>P. chloritidismutans</i>	No specific genes mentioned	(Not specified)
Other	14 chromosomal mutations in <i>gyrA</i> genes, 22 chromosomal mutations in <i>parC</i> genes, Multiple drug-resistant genes (not specifically listed), 16srRNA methyltransferase: <i>ArmA</i> , <i>rmtB</i> , <i>rmtC</i> , <i>rmtF</i> genes	(Not specified)

proliferation of carbapenemase genes. Additionally, the lack of strong infection control procedures in many healthcare settings promotes the transfer of carbapenem-resistant bacteria between patients. This has been compounded by poor wastewater management, particularly in metropolitan areas which allows antibiotic residues and resistant bacteria into the environment, facilitating the spread of resistance genes among environmental microorganisms. This environmental reservoir provides a breeding ground for resistant infections, which can re-enter clinical settings via contaminated water or food.

Additionally, the method utilized to isolate and identify *Pseudomonas* spp. has a substantial impact on gene detection for resistance and virulence. Traditional culture was the most common method reported at 70% across various studies in the Community as presented in Figure 3. The reason could be due to its low cost and simplicity but it's limited ability to detect specific genetic resistance mechanisms and virulence factors. Molecular approaches provide a more thorough understanding of resistance and pathogenicity, but they are neglected due to resource and infrastructure constraints. Expanding the use of molecular techniques in East African Community would improve the discovery of important resistance and virulence genes, hence improving patient outcomes and influencing public health efforts to battle *Pseudomonas* infections.

Furthermore, this study found the prevalence of high-risk clones such as ST 244 and ST 357 reported across various studies as presented in Table 4. The results demonstrated the clonal spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* strains across East African Community. These clones include both resistance and virulence genes, making them more harmful in clinical settings.^{44,45} The fast clonal proliferation of these high-risk strains is aided by factors such as patient transfers between hospitals, congested healthcare facilities, and inadequate infection control methods. Inadequate sterilization methods and a lack of isolation measures for infected

Table 4. *Pseudomonas* strains sequenced.

Organism	Strain	Reference
<i>Pseudomonas aeruginosa</i>	Global High-risk clones: ST 244 & ST 357; 56 <i>P.aeruginosa</i> , clinical isolates; High Risk STs: 357, 654; Local High-risk clones: ST 2025, ST 455 & ST 233; Carbapenem resistant <i>P. aeruginosa</i> ; STs 316, 357, 654 & 1203; 13 <i>Pseudomonas aeruginosa</i> isolated; Novel MDR clone with virulence genes: ST 3674	44-46
<i>Pseudomonas aeruginosa</i>	NA	49,51-54
<i>Pseudomonas pseudoalcaligenes</i>	NA	50

Methods of Genomic Characterisation




Figure 5. Methods of genomic characterization and sequencing.

patients allow MDR and XDR clones to spread within and between institutions. Also, the existence of these clones in environmental reservoirs, such as hospital wastewater systems, ensures their persistence and circulation outside clinical settings, which increases the chance of reintroduction into healthcare facilities. The most common method utilized for the detection of these high-risk clones as reported was DNA extraction and PCR at 30%. The reason for this method being increasingly frequent in the East African Community is also+ due to its low cost, availability, simplicity, speed, and effectiveness in detecting specific, therapeutically important resistance genes in resource-limited settings. Other methods reported include quantitative PCR, whole genome sequencing, the Modified Hodge Test (MHT) for carbapenemase activity, the Imipenem-EDTA double disk synergy test for metallo-beta-lactamase activity, and basic PCR as presented in Figure 5.

Pseudomonas aeruginosa reported across various studies in the East African Community had a lower resistance rate (54%) than clinical isolates (73%).⁴⁸ This finding demonstrates the differences in selecting forces between clinical and environmental settings. This could be because antibiotics are not used extensively in natural habitats, and environmental isolates are subjected to lesser levels of selective pressure, resulting in lower resistance rates. However, environmental bacteria can still serve as repositories for resistance genes, particularly in locations where antibiotic poisoning of water supplies is frequent. As the East African Community faces issues connected to industrial and hospital waste management, the environment becomes a crucial reservoir for resistant strains, which may eventually infect humans through contaminated water or food.

Table 5. Countries and number of studies reported.

Country	Frequency	Percentage	Region
DRC	2	20%	Kinshasa, South Kivu District
Kenya	4	40%	Lake Bogoria of the Great Rift Valley, Nairobi (Agha Khan hospital), Six hospitals in Nairobi & Kisii
Tanzania	2	20%	Northwestern, Northwestern region (Mwanza Hospital)
Uganda	3	30%	Mbarara Referral Hospital, Mulago hospital Kampala

The majority of the studies reporting *Pseudomonas aeruginosa* resistance were conducted in Kenya (30%) in numerous locations including urban centers like Nairobi and rural areas like Lake Bogoria.⁴⁵ Followed by 30% in Uganda, next to Kenya in terms of the proportion of studies addressing the topic, indicating a growing awareness of antibiotic resistance and a greater capability for healthcare research. Uganda has made tremendous progress in creating research projects, with institutions like Makerere University and Kampala International University adding to the corpus of knowledge on antibiotic resistance. Studies in Tanzania and the Democratic Republic of the Congo (DRC) are more limited, with an emphasis on specific locations such as Tanzania's Mwanza both accounting for 20%. Kenya's more modern healthcare infrastructure and research institutes offer a more comprehensive examination of resistance patterns in both rural and urban areas. The increased frequency of studies in Kenya may also reflect the country's dedication to combating antibiotic resistance, which is supported by both local and international research funding. Tanzania and the Democratic Republic of the Congo, on the other hand, confront more obstacles in terms of healthcare resources and research competence, restricting the extent of studies and potentially underestimating the true extent of antimicrobial resistance in these countries as summarized in [Table 5](#).

Conclusion

This systematic review revealed the major impact of antibiotics and environment on gene expression patterns of *Pseudomonas spp.* in East Africa Community. The extensive resistance identified, notably in *Pseudomonas aeruginosa* clinical isolates, highlights the importance of unregulated antibiotic use, inadequate healthcare infrastructure, and environmental pollution in generating antimicrobial resistance. Although amikacin is still a potential choice due to its low resistance, the significant incidence of carbapenem-resistant genes (e.g., *blaNDM-1*, *blaVIM*) and the clonal proliferation of MDR/XDR *Pseudomonas* strains highlight the need for improved infection control and stewardship initiatives. Furthermore, the research finds that, while classic culture methods remain dominant, there is an increasing need to use molecular techniques for improved genomic characterization and resistance identification in the East African Community to improve patient's outcome.

Recommendations

1. Healthcare institutions in East Africa must develop strict antimicrobial stewardship programs to monitor and restrict antibiotic consumption, decreasing unnecessary prescriptions and limiting self-medication.
2. Investment in molecular technologies such as quantitative PCR and whole-genome sequencing is required to improve resistance gene and virulence factor detection.
3. To restrict the transmission of MDR/XDR strains, hospitals should establish stronger infection control measures, such as adequate sterilization and isolation protocols.
4. Governments should impose antibiotic-use controls in livestock husbandry to prevent the spread of resistance from animals to people via food.
5. Improve environmental waste management, particularly in metropolitan areas, to prevent the spread of resistant bacteria through water and food systems.

Limitations of the study

1. While Kenya and Uganda had a large number of studies, data from Tanzania and the DRC were scarce, potentially underestimating overall resistance levels in East Africa.
2. Limited utilization of molecular methods due to resource and infrastructure restrictions may result in under-reporting of critical resistance mechanisms.
3. The emphasis on studies published in English or accessible databases may have resulted in a bias that excluded valuable research from other sources.
4. The employment of various antimicrobial sensitivity testing methodologies across studies may have contributed to variations in resistance detection.

Preprint information

<https://doi.org/10.1101/2024.12.23.630126> (Vandu, C. D., Fasogbon, I. V., Agbaje, A. B., Anyanwu, C. N., Wusa, M., Ikuomola, E.O., ... & Aja, P.M. (2024). Impact of Antibiotics on the Genomic expression of *Pseudomonas aeruginosa* in the East African Community: A systematic Review. BioRxiv, 2024-12).

Data availability

All datasets can be accessed from the open science framework: (Angela Mumbua Musyoka; 2025; IMPACT OF ANTIBIOTICS ON THE GENOMIC EXPRESSION OF *Pseudomonas aeruginosa* IN THE EAST AFRICAN COMMUNITY: A SYSTEMATIC REVIEW; Open Science Framework; <https://doi.org/10.17605/OSF.IO/BRJVF>).⁵⁵

Data repository for the article: Open Science Framework (<https://osf.io/brjvf/files/osfstorage>)

Data repository DOI: [10.17605/OSF.IO/BRJVF](https://doi.org/10.17605/OSF.IO/BRJVF)

License: [CCO 1.0 universal](https://creativecommons.org/licenses/by/4.0/)

References

1. Darwesh O, Matter I: *Pseudomonas aeruginosa: New Perspectives and Applications*. BoD-Books on Demand; 2024.
2. Hafiz S, et al.: **Antimicrobial resistance of *Pseudomonas aeruginosa*: navigating clinical impacts, current resistance trends, and innovations in breaking therapies.** *Front. Microbiol.* 2023.
3. Salim SA, Mohan MS, Forgia N, et al.: **Medical Importance of ESKAPE Pathogens.** *ESKAPE Pathogens: Detection, Mechanisms and Treatment Strategies*. Singapore: Springer Nature Singapore; 2024; pp. 1–32.
4. Wood SJ, et al.: ***Pseudomonas aeruginosa*: Infections, Animal Modeling, and Therapeutics.** *Cells*. 2023; **12**.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Zhang L, Tian X, Sun L, et al.: **Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance.** *Pharmaceutics*. 2024; **16**(2): 170.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Mudgil U, Khullar L, Chadha J, et al.: **Beyond antibiotics: Emerging antivirulence strategies to combat *Pseudomonas aeruginosa* in cystic fibrosis.** *Microb. Pathog.* 2024; **193**: 106730.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Huynh TQ, Tran NBV, Pham TTV, et al.: **Adaptive response of *Pseudomonas aeruginosa* under serial ciprofloxacin exposure.** *Microbiology*. 2024; **170**(3): 001443.
[Publisher Full Text](#)
8. Marmolejo Lozano JD: **Exploring growth rate influence on quorum sensing: from dynamics to antibiotic responses.** 2024.
9. Morita Y, Tomida J, Kawamura Y: **MexXY multidrug efflux system of *Pseudomonas aeruginosa*.** *Front. Microbiol.* 2020; **11**: 2077.
10. Santos AL, Liu D, van Venrooy A, et al.: **Nonlethal Molecular Nanomachines Potentiate Antibiotic Activity Against Gram-Negative Bacteria by Increasing Cell Permeability and Attenuating Efflux.** *ACS Nano*. 2024; **18**(4): 3023–3042.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. David A, Tahrioui A, Duchesne R, et al.: **Membrane fluidity homeostasis is required for tobramycin-enhanced biofilm in *Pseudomonas aeruginosa*.** *Microbiology Spectrum*. 2024; **12**(4): e02303–e02323.
[Publisher Full Text](#)
12. Abdullah S, Younis K: **The Impact of Minimum Inhibitory and Sub Inhibitory Concentrations of Antibiotics on *Acinetobacter baumannii* and *Pseudomonas aeruginosa* Biofilm Production.** *Egypt. J. Vet. Sci.* 2024; **55**(5): 1423–1433.
[Publisher Full Text](#)
13. Blevins R, et al.: **Gene Expression Profiling of *Pseudomonas aeruginosa* Upon Exposure to Colistin and Tobramycin.** *Front. Microbiol.* 2018.
14. Araújo D, Silva AR, Fernandes R, et al.: **Emerging Approaches for Mitigating Biofilm-Formation-Associated Infections in Farm, Wild, and Companion Animals.** *Pathogens*. 2024; **13**(4): 320.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Wang L, Gu B, Zhang L, et al.: **Recent Advances in Bacterial Biofilm Studies: Formation, Regulation, and Eradication in Human Infections.** 2024.
16. Almutairy B: **Extensively and Multidrug Resistance bacterial strains: Case Studies of Antibiotics Resistance.** *Front. Microbiol.* 2024; **15**: 1381511.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Fernando DM, Tun HM, Poole J, et al.: **CIP Resistance and qnr Genes in *Pseudomonas aeruginosa* from Canadian Swine Production Environments.** *Frontiers in Veterinary Science*. 2021; **8**: 754937.
18. Cecil RE, Yoder-Himes DR: **Examining the influence of environmental factors on *Acanthamoeba castellanii* and *Pseudomonas aeruginosa* in co-culture.** *Plos one*. 2024; **19**(6):

- e0305973.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Cardoza E, Singh H: **From Stress Tolerance to Virulence: Recognizing the Roles of Csps in Pathogenicity and Food Contamination.** *Pathogens.* 2024; **13**(1): 69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Erkihun M, Asmare Z, Endalamew K, et al.: **Medical Scope of Biofilm and Quorum Sensing during Biofilm Formation: Systematic Review.** *Bacteria.* 2024; **3**(3): 118–135.
[Publisher Full Text](#)
 21. Ni B, Zhang TL, Cai TG, et al.: **Effects of heavy metal and disinfectant on antibiotic resistance genes and virulence factor genes in the plastsphere from diverse soil ecosystems.** *J. Hazard. Mater.* 2024; **465**: 133335.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Kim S, Gibb B, Gray KM: **Quaternary ammonium compounds impact the structure and function of bacterial biofilms.** *Environ. Sci. Technol.* 2018; **52**(17): 10215–10225.
 23. Lu Z, Mahony AK, Arnold WA, et al.: **Quaternary ammonia compounds in disinfectant products: evaluating the potential for promoting antibiotic resistance and disrupting wastewater treatment plant performance.** *Environmental Science: Advances.* 2024; **3**(2): 208–226.
[Publisher Full Text](#)
 24. Sauer K, Cullen MC, Rickard AH, et al.: **Characterization of nutrient-induced dispersion in *Pseudomonas aeruginosa* PAO1 biofilm.** *J. Bacteriol.* 2019; **186**(21): 7312–7326.
[Publisher Full Text](#)
 25. Ungor I, Apidianakis Y: **Bacterial synergies and antagonisms affecting *Pseudomonas aeruginosa* virulence in the human lung, skin and intestine.** *Future Microbiol.* 2024; **19**(2): 141–155.
[Publisher Full Text](#)
 26. Ambreetha S, Zincke D, Balachandar D, et al.: **Genomic and metabolic versatility of *Pseudomonas aeruginosa* contributes to its inter-kingdom transmission and survival.** *J. Med. Microbiol.* 2024; **73**(2): 001791.
[Publisher Full Text](#)
 27. Murray LM, Hayes A, Snape J, et al.: **Co-selection for antibiotic resistance by environmental contaminants.** *npj Antimicrobials and Resistance.* 2024; **2**(1): 9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Goff JL, Lui LM, Nielsen TN, et al.: **Mixed waste contamination selects for a mobile genetic element population enriched in multiple heavy metal resistance genes.** *ISME communications.* 2024; **4**(1): ycae064.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Martínez JL, Coque TM, Baquero F: **Prioritizing risk of antibiotic resistance genes in all metagenomes.** *Nat. Rev. Microbiol.* 2020; **18**(5): 295–304.
 30. Flemming HC, Wingender J, Szewzyk U, et al.: **Biofilms: an emergent form of bacterial life.** *Nat. Rev. Microbiol.* 2019; **17**(9): 536–551.
 31. Yang X, Zeng Q, Gou S, et al.: **Phenotypic heterogeneity unveils a negative correlation between antibiotic resistance and quorum sensing in *Pseudomonas aeruginosa* clinical isolates.** *Front. Microbiol.* 2024; **15**: 1327675.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Sendra E, Fernández-Muñoz A, Zamorano L, et al.: **Impact of multidrug resistance on the virulence and fitness of *Pseudomonas aeruginosa*: a microbiological and clinical perspective.** *Infection.* 2024; **52**: 1235–1268.
[Publisher Full Text](#)
 33. Yang W, Li J, Yao Z, et al.: **A review on the alternatives to antibiotics and the treatment of antibiotic pollution: Current development and future prospects.** *Sci. Total Environ.* 2024; **926**: 171757.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Kleinman A: **A Review of Natural Selection and Selection Pressures in the Practice of Medicine.** 2024.
 35. Guo T, Yang L, Zhou N, et al.: **Subminimum Inhibitory Concentrations Tetracycline Antibiotics Induce Biofilm Formation in Minocycline-Resistant *Klebsiella pneumoniae* by Affecting Bacterial Physical and Chemical Properties and Associated Genes Expression.** *ACS Infectious Diseases.* 2024; **10**: 2929–2938.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Yousefi Nojookambari N, Eslami G, Sadredinamin M, et al.: **Sub-minimum inhibitory concentrations (sub-MICs) of colistin on *Acinetobacter baumannii* biofilm formation potency, adherence, and invasion to epithelial host cells: an experimental study in an Iranian children's referral hospital.** *Microbiology Spectrum.* 2024; **12**(2): e02523–e02523.
[Publisher Full Text](#)
 37. Akbari FH: **An overview of Stress in cellular and molecular levels and the importance of studying responses to stresses in biology.** *Life Science Journal.* 2024; **21**(3).
 38. Fasogbon IV, Yakubu MN, Adam M, et al.: **NON-SELEX-BASED IN-SILICO MODELED APTAMERS AGAINST SARS-COV-2 PROTEINS: A SYSTEMATIC REVIEW.** *KUJ. Health Scii.* 2022; **2**(1): 69–79.
 39. Fasogbon IV, Aja PM, Ondari EN, et al.: **UCP-LF and other assay methods for schistosome circulating anodic antigen between 1978 and 2022.** *Biology Methods and Protocols.* 2023; **8**(1).
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Fasogbon IV, Ondari EN, Deusdedit T, et al.: **Point-of-care potentials of lateral flow-based field screening for *Mycoplasma bovis* infections: a literature review.** *Biology Methods and Protocols.* 2024; **9**(1): bpae034.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Page MJ, McKenzie JE, Bossuyt PM, et al.: **The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.** *The BMJ.* 2021; **372**.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Mustapha A, Chidiebere O, Victor FI, et al.: **Antibacterial activity of Nigerian medicinal plants as panacea for antibiotic resistance: A systematic review.** *Journal of Medicinal Herbs.* 2022; **13**(3): 11–23.
 43. Johnson N, Phillips M: **Rayyan for systematic reviews.** *J. Electron. Resour. Librariansh.* 2018; **30**(1): 46–48.
[Publisher Full Text](#)
 44. Musila L, Kyanya C, Maybank R, et al.: **Detection of diverse carbapenem and multidrug resistance genes and high-risk strain types among carbapenem non-susceptible clinical isolates of target gram-negative bacteria in Kenya.** *PLoS One.* 2021; **16**(2): e0246937.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Kiyaga S, Kyanya C, Muraya AW, et al.: **Genetic diversity, distribution, and genomic characterization of antibiotic resistance and virulence of clinical *Pseudomonas aeruginosa* Strains in Kenya.** *Front. Microbiol.* 2022; **13**: 835403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Aruhomukama D, Najjuka CF, Kajumbula H, et al.: **Bla VIM-and bla OXA-mediated carbapenem resistance among *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates from the Mulago hospital intensive care unit in Kampala, Uganda.** *BMC Infect. Dis.* 2019; **19**: 1–8.
[Publisher Full Text](#)
 47. Mushi MF, Mshana SE, Imirzalioglu C, et al.: **Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania.** *Biomed. Res. Int.* 2014; **2014**(1): 1–6.
[Publisher Full Text](#)
 48. Kateete DP, Nakanjako R, Namugenyi J, et al.: **Carbapenem resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* at Mulago hospital in Kampala, Uganda (2007–2009).** *Springerplus.* 2016; **5**: 1–11.
 49. Moremi N, Claus H, Mshana SE: **Antimicrobial resistance pattern: a report of microbiological cultures at a tertiary hospital in Tanzania.** *BMC Infect. Dis.* 2016; **16**: 1–7.
[Publisher Full Text](#)
 50. Al Salah DMM, Laffite A, Poté J: **Occurrence of bacterial markers and antibiotic resistance genes in sub-Saharan rivers receiving animal farm wastewaters.** *Sci. Rep.* 2019; **9**(1): 14847.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Khalim W, Mwesigye J, Tungotyo M, et al.: **Resistance pattern of infected chronic wound isolates and factors associated with bacterial resistance to third generation cephalosporins at Mbarara Regional Referral Hospital, Uganda.** *Plos one.* 2021; **16**(12): e0261264.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Price LB, Liu CM, Johnson KE, et al.: **The effects of circumcision on the penis microbiome.** *PLoS one.* 2010; **5**(1): e8422.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Ireng LM, Kabego L, Kinunu FB, et al.: **Antimicrobial resistance of bacteria isolated from patients with bloodstream infections at a tertiary care hospital in the Democratic Republic of the Congo.** *S. Afr. Med. J.* 2015; **105**(9): 752–755.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Jin S: ***Pseudomonas aeruginosa*.** *Molecular Medical Microbiology.* Academic Press; 2024; pp. 811–825.
 55. Musyoka AM: **IMPACT OF ANTIBIOTICS ON THE GENOMIC EXPRESSION OF *Pseudomonas aeruginosa* IN THE EAST AFRICAN COMMUNITY: A SYSTEMATIC REVIEW.** Open Science Framework; 2025.
[Publisher Full Text](#)
 56. Vandu CD, Fasogbon IV, Agbaje AB, et al.: **Impact of Antibiotics on the Genomic expression of *Pseudomonas aeruginosa* in the East African Community: A systematic Review.** *BioRxiv.* 2024; 2012–2024.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research